John de Groot, MD

Medical Advisor

Dr. John de Groot is a Professor, and Chairman ad interim, in the Department of Neuro-Oncology at The University of Texas MD Anderson Cancer Center. He is an expert in the fields of glioma angiogenesis and molecularly targeted therapy. He completed his medical education at The University of Texas Medical Branch at Galveston, and pursued internship and residency at Johns Hopkins School of Medicine.

Following a clinical fellowship at MD Anderson, de Groot joined the faculty in 2004. His translational research program has produced critical insights into how gliomas respond to and resist killing by anti-angiogenic agents and illuminated therapeutic approaches employed in clinical trials to overcome this resistance. De Groot has also significantly contributed to the discovery of biomarkers of response and progression in glioblastoma patients treated with anti-angiogenic therapy, and as a result has opened multiple biomarker-driven clinical trials.

Dr. de Groot has served as the principal investigator (PI) or co-investigator on multiple funded National Cancer Institute, foundation, and industry-sponsored grants. He is the PI of numerous clinical trials involving novel agents being tested in patients with glioblastoma and is a leader of MD Anderson’s Glioblastoma Moon Shot. As director of the Neuro-Oncology Fellowship Program, he is also helping develop the next generation of neuro-oncologists.

Dr. de Groot has eighty peer reviewed articles. He is or has been a peer reviewer for 23 scientific journals, both national & international, and is on four editorial review boards.